Results. In patients with early RA (the ASPIRE trial), ACR/EULAR Boolean, CDAI, and SDAI remission rates at 6-7 months were 4-6% for methotrexate (MTX) alone versus 11-14% for infliximab plus MTX. In patients with MTX-refractory active RA (the ATTRACT and GO-FORWARD trials), remission rates were £1% for comparator (add-on of placebo) versus 4-6% for add-on of infliximab in the ATTRACT trial and £3% for comparator (add-on of placebo) versus 11-13% for add-on of golimumab in the GO-FORWARD trial. Existing remission cut points of different measures were generally comparable, with the Boolean criteria being somewhat more stringent than the SDAI and CDAI criteria. Remission rates were similar across definitions, as was average statistical power (CDAI, 55.6%; Boolean, 59.9%; SDAI, 62.6%).
Conclusion. Remission is an ambitious primary end point for RA clinical trials, to be reserved for selected scenarios based on power considerations. The ACR/ EULAR definitions are interchangeable, with slightly higher stringency of Boolean criteria over index-based criteria.
Assessment of response to therapy in rheumatoid arthritis (RA) has evolved over the past 2 decades. While in earlier years, observation of response was considered a sufficient treatment success, more recently, the importance of achieving a "good" state of disease activity has moved into the foreground. These developments peaked in the publication of the "treat-to-target" principle for RA (1) , which clearly defined disease activity states as important targets for RA patients. Around the same time, the first joint effort of the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) resulted in recommendations for reporting clinical trial outcomes that included proportions of patients achieving low disease activity and remission in addition to standard "response" end points (2) .
However, using a stringent dichotomous measure (e.g., presence/absence of remission) as a primary clinical trial outcome can challenge the study design. Previous work has shown that lenient dichotomous outcome definitions, such as the ACR criteria for 20% improvement in disease activity (ACR20) (3), show much greater power than more rigorous ones (4) , while at the same time rheumatologists widely agree on the irrelevance of ACR20 responses in clinical practice. The strategy of treating RA not to a specific response, but instead toward reaching a specific disease activity target, has been advocated (1) , and it is now a core element of most of the established RA management recommendations (5, 6) .
In these international recommendations, as well as in many national recommendations, remission has been proposed as a stringent contemporary treatment target. The functional and structural benefits of remission are clearly substantiated by evidence, even when compared with low disease activity (7) . A committee comprising ACR, EULAR, and Outcome Measures in Rheumatology initiative members has recently recommended specific measures appropriate for assessing remission in clinical trials. These measures included a Boolean-based approach, centered on fulfilling several individual measures in parallel, and an index-based approach using a Simplified Disease Activity Index (SDAI) score (8) of #3.3 as a criterion for remission (9) . Alternatively, the criterion of a score of #2.8 on the Clinical Disease Activity Index (CDAI) (10) is an index-based definition specifically designed for clinical practice (9) . Other measures, including the Disease Activity Score in 28 joints (DAS28) (11), were not recommended, as they lacked validity for their remission definition.
Since their publication in 2011, the proposed remission criteria have not been formally compared for consistency in clinical trials regarding stringency, power, and face validity. This is the purpose of the present study, in which we used data derived from 3 phase III trials conducted to evaluate the anti-tumor necrosis factor (anti-TNF) agents infliximab and golimumab in patients with either early RA or active RA despite methotrexate (MTX) therapy (MTX-refractory active RA).
PATIENTS AND METHODS
Clinical trials. The clinical trials contributing data to these analyses were conducted according to current Declaration of Helsinki and Good Clinical Practice guidelines. The study protocols were approved by governing ethical review boards, and all patients provided written informed consent prior to studyrelated evaluations.
The efficacy and safety of the chimeric anti-TNF monoclonal antibody (mAb) infliximab were evaluated in MTX-naive patients with early RA in the ASPIRE (Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset) trial (ClinicalTrials.gov identifier: NCT00236028) (12) and in patients with MTX-refractory active RA in the ATTRACT (Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy) trial (ClinicalTrials.gov identifier: NCT00269867) (13) . The human anti-TNF mAb golimumab was evaluated in patients with MTXrefractory active RA in the GO-FORWARD trial (ClinicalTrials.gov identifier: NCT00264550) (14) . Patient selection criteria and details of study designs have been reported for the ASPIRE (12), ATTRACT (13) , and GO-FORWARD (14) Remission criteria. The 2011 ACR/EULAR remission criteria allow for the assessment of remission using a Boolean definition (with parallel fulfillment of several criteria) and an index-based definition (i.e., the SDAI). Achieving Boolean-based remission requires scores of #1 on each of the following 4 core measures: 28-joint swollen joint count (SJC; range 0-28), 28-joint tender joint count (TJC; range 0-28), patient's global assessment of disease activity on a 0-10-cm visual analog scale (VAS), and serum C-reactive protein (CRP) level (range 0-10 mg/dl) (9) .
The SDAI (8) is a patient, provider, and laboratory composite tool that sums the SJC, TJC, physician's global assessment of disease activity (in cm on a 0-10-cm VAS), patient's global assessment of disease activity (in cm), and CRP level (in mg/dl) to yield a single score on a continuous scale (range 0-86, assuming a CRP level of #10 mg/dl). An SDAI score of #3.3 denotes remission (8) .
The CDAI (10) was proposed as an alternative indexbased measure, particularly for use in routine clinical settings without the availability of acute-phase reactant measures. It is a patient and provider composite tool that sums the 28-joint SJC, 28-joint TJC, physician's global assessment of disease activity (0-10-cm VAS), and patient's global assessment of disease activity (0-10-cm VAS) to yield a single score on a continuous scale (range 0-76). Thus, the CDAI is the SDAI minus the CRP level. A CDAI score of #2.8 indicates clinical remission (10).
DAS28 using the CRP level (DAS28-CRP) as an additional remission criterion. The DAS28-CRP (11, 15) is also a patient, provider, and laboratory composite tool that incorporates the 28-joint SJC, 28-joint TJC, patient's global assessment of disease activity (0-100-mm VAS), and serum CRP level, but it requires differential weighting of individual indices (TJC is weighted more than SJC) in the derivation of a single score on a continuous scale (range 0-9.4). A DAS28-CRP value of ,2.6 has been defined as clinical remission (16) . Herein, we present the DAS28-CRP results for the core analyses in comparison to the ACR/EULAR definitions.
Statistical analysis. To approximate the conditions of clinical trials, the analyses applied statistical rigor as though each remission end point constituted a primary end point, such that missing data were imputed by last observation carried forward methodology, and other rules were implemented as defined in the statistical analysis plan of each study (12) (13) (14) . Generally, initiation of disease-modifying antirheumatic drugs except for MTX, an increase in the dosage of MTX or oral glucocorticoids, and/or administration of intravenous/intramuscular glucocorticoids for RA were defined as criteria for failure of treatment. If any of these occurred before the end point in question, then the patient was considered not to have achieved remission. For the GO-FORWARD trial, patients who qualified for early escape at week 16 had subsequent data replaced by week-16 values; data handling rules for week-24 end points also were applied for early escape (14) .
Patients who discontinued treatment were encouraged to return for scheduled follow-up assessments. Patients with no observed data for the end point were defined as not achieving remission.
The various remission rates were compared between anti-TNF and comparator groups using Fisher's exact test. We also assessed different types of validity based on the existing remission definitions, estimated sample sizes for future studies, and assessed the effect of patient selection criteria on achieving remission, as detailed below.
Internal validity of remission cut point within each metric. We assessed how variations of established cut points defining remission would affect power in clinical studies by varying the cut points ranging from 0 to 6 by 0.1 for the Boolean definition and by varying the cut points ranging from 0 to 30 by 0.1 for the SDAI and CDAI definitions. Power calculations were based on the observed remission rates for the anti-TNF and comparator groups in the ATTRACT trial by using a chi-square test with a 5 0.05.
Face validity of remission cut points. We subsequently asked the question of what constitutes a state of remission by the different definitions and whether this would reflect current clinical understanding and conceptualization of a state of remission. One obvious clinical marker for this purpose is the number of swollen joints remaining when remission is reached. We therefore provide the frequency counts of the number of patients with disease in remission who have 0, 1, or 2 residual swollen joints as well as the means and the ranges of the number of residual swollen joints across the different definitions.
Comparative validity of existing remission criteria. Since the different definitions are based on different scales and metrics, slightly different rates of remission are achieved. In this next step, we identified for each scale using its established remission cut point the corresponding cut points on the respective other scales that would lead to a similar proportion of patients with disease in remission. Since these identical proportions will likely not comprise identical patients, we also assessed the cut points of the different scales corresponding to the same power (given a fixed sample size; see below).
Sample size estimations for future studies. In the next step of these analyses, we constructed models to estimate the sample size requirements for future studies by modifying the power requirements as well as by looking at the implications of selecting study populations for specific characteristics. The statistical power to compare an anti-TNF treatment group to a comparator group was determined at a 5% level of significance with 100 patients per group using the individual populations of the 3 studies. Assumptions regarding remission rates were based on the rates observed at the comparable time points across the trials (i.e., week 30 in the ASPIRE and ATTRACT trials and week 24 . Sample sizes to achieve 70%, 80%, and 90% power for a hypothetical future study based on each of the 3 studies' results for each remission end point at the comparable time points were determined based on a 2-sided chi-square test (17) . Disease activity inclusion requirements and population effects. In these analyses, we assessed the effects of different baseline characteristics on the chance of reaching remission to evaluate how selection of particular patient groups at entry into a clinical trial may affect the power for achieving a given end point. We determined the sample size required to achieve 90% power for SDAI remission based on the baseline SDAI score; remission rates had been estimated by a logistic regression analysis with the baseline SDAI score as a covariate and treatment group (comparator or anti-TNF dose producing the highest remission rate) as a factor. We also used a logistic regression analysis to assess the impact of the baseline SDAI score on SDAI remission for anti-TNF treatment at weeks 30 and 54 in the ASPIRE and ATTRACT trials and at weeks 14 and 24 in the GO-FORWARD trial.
In supplementary logistic regression analyses, the SDAI remission rate was predicted by the baseline SDAI score for each study. Analyses of SDAI remission rates in the large ASPIRE trial also were performed using a univariate logistic regression analysis to assess the potential effects of treatment and a baseline factor (e.g., age, SJC). The model includes the main effects of treatment and the factor as well as the interaction between them. The factors were either categorical or continuous. The significance levels for each component in the model were determined. We report the relative risk (RR) and 95% confidence interval (95% CI) of remission for treatment relative to comparator within each level of categorical factors and for divisions of continuous variables as were used in the primary study analyses.
RESULTS
Clinical remission rates. Clinical remission rates using the Boolean, SDAI, and CDAI criteria at 2 time points (see Supplementary Table 1 , http://onlinelibrary. wiley.com/doi/10.1002/art.39945/abstract) in each study are shown in Table 1 . Remission rates were generally significantly higher in the anti-TNF group than in the comparator group at both time points assessed for each end point applied, with 1 exception (the CDAI in the ATTRACT trial). Remission rates generally were lower for Boolean remission than those for SDAI and CDAI scores, which were relatively similar. Remission rates also were lower in patients with MTX-refractory active RA than in those with early RA.
Internal validity of remission cut point within each metric. To further assess the stringency of each remission end point, we determined power while varying the cut points, ranging from 0 to 6 by 0.1 for the Boolean criteria and ranging from 0 to 30 by 0.1 for the SDAI and CDAI definitions. Although increasing the threshold to define remission obviously raises the proportion of patients qualifying for remission for every end point, the effects on their discriminant abilities are unclear. As shown in Figure  1A for week 30 in the ATTRACT infliximab trial of patients with MTX-refractory active RA, the Boolean end point is very stringent and typically has lower power with its standard cut point at 1 compared with hypothetically higher cut points. The CDAI and SDAI, which differ by exclusion and inclusion, respectively, of CRP level, tend to trend together. Compared with their established cut points, more lenient (higher) remission cut points were accompanied by higher power.
External validity of remission end points. Face validity was assessed using the SJC as the reference criterion (i.e., patients with disease in remission should have only a few, and ideally no, swollen joints). By definition, the maximum SJCs allowable for Boolean, SDAI, and CDAI remission are 1, 2, and 2, respectively. At week 30 in the ASPIRE trial, the respective proportions of patients with an SJC of 0, 1, or 2 were 79.6%, 20.4%, and 0.0% for those with disease in Boolean remission (average SJC of 0.2); 82.6%, 13.9%, and 3.5% for those with disease in CDAI remission (average SJC of 0.2); and 83.5%, 12.8%, and 3.7% for those with disease in SDAI remission (average SJC of 0.2). Similar findings were observed in the GO-FORWARD trial at week 24 (Table 2 ). Although the proportion of patients with an SJC of 2 was slightly higher for those with disease in SDAI and CDAI remission compared with those with disease in Boolean remission, the average number of joints with active disease was very similar. As such, all 3 indices expressed similar and high degrees of clinical face validity in that they do not allow swollen joints in their remission definition.
Results of comparative validity assessments made by determining cut points similarly rigorous for remission indicated that the Boolean end points were somewhat more stringent than the SDAI and CDAI criteria. To achieve proportions of patients with remission comparable to proportions of patients with Boolean remission, cut points would need to be lowered by 0.5-1.9 for the SDAI and by 0.3-0.7 for the CDAI. Conversely, the Boolean cut point would need to be increased to 1.5 to approximate the proportions of patients with SDAI/CDAI remission, which were again very similar (Table 3 , left columns). * DAS28-CRP 5 Disease Activity Score in 28 joints using the C-reactive protein level; SJC 5 swollen joint count (see Table 1 for other definitions and for descriptions of trials). Subsequent comparisons of remission cut points that would yield similar power indicated that the observed powers of existing cut points were very similar (Table 3 , right columns, numbers in brackets). As also noted in the internal analysis above, the slightly more lenient SDAI/CDAI definitions have greater power than the more stringent Boolean definition. The more robust comparator response in the ASPIRE trial (placebo plus de novo MTX control in MTXnaive patients) versus that in the ATTRACT trial (placebo plus continued MTX control in patients with MTXrefractory active RA) yielded smaller treatment differences, and thus lower power, in the ASPIRE trial.
Sample size estimations for future studies. As noted, for a given number of patients per treatment group (i.e., 100), the statistical power tended to be similar for the CDAI (range 41.5-81.8%, average 55.6%), Boolean (range 45.3-77.8%, average 59.9%), and SDAI (range 41.9-78.8%, average 62.6%) remission end points. In determining numbers of patients per treatment group based on the various remission end points and statistical power ranging from 70% to 90% (Table  4) , power was generally higher in the studies comparing institution of an active drug with institution of placebo (ATTRACT, GO-FORWARD) than in the study comparing 2 active regimens (ASPIRE) ( Table 4) . Also, power for the remission end point was greater for the GO-FORWARD study than for the ATTRACT study. Although the populations were similar, disease activity inclusion requirements differed across trials (see Supplementary Table 1 , http://onlinelibrary.wiley.com/doi/10. 1002/art.39945/abstract), which likely explains this finding. Further analysis of this concept is described below.
Disease activity inclusion requirements. The baseline mean SDAI scores were 47.5 in the ASPIRE trial, 45.9 in the ATTRACT trial, and 35.2 in the GO-FORWARD trial (see Supplementary Table 1 , http:// onlinelibrary.wiley.com/doi/10.1002/art.39945/abstract). Translating the impact of baseline disease activity into power, approximate sample sizes of 50-100 and $150-200 patients per group, respectively, would be required for future studies of patients with median baseline SDAI scores of 15 and 45 ( Figure 1B) .
Logistic regression analyses incorporating baseline SDAI score as an independent variable were conducted to assess the effects of baseline disease activity on SDAI remission (parameter estimates are shown in Supplementary Table 2, http://onlinelibrary.wiley.com/ doi/10.1002/art.39945/abstract). Based on these logistic models, the predicted achievement of SDAI remission by baseline SDAI score for each study indicated that * DAS28-CRP 5 Disease Activity Score in 28 joints using the C-reactive protein level (see Table 1 for other definitions). † Combined doses analyzed (see Table 1 for descriptions of trials). ‡ Based on comparison between anti-TNF and comparator groups, with 100 patients per group and level of significance of 0.05 using the remission rates shown for each remission end point and study. If the comparator rate was 0, then 0.1% was used for power calculation. * CRP 5 C-reactive protein; HAQ DI 5 Health Assessment Questionnaire disability index (see Table 1 for other definitions and for descriptions of trials). † Inconsistencies between denominators and those in Table 1 are due to missing data for the baseline covariate variable. ‡ Relative risk (RR) of infliximab to the comparator was estimated for remission determined by the SDAI. § Statistically significant difference between infliximab and comparator as determined by logistic regression analysis of SDAI remission at week 54 on treatment, baseline covariate, and treatment-baseline covariate interaction (RRs .2.5 and 95% confidence intervals [95% CIs] exclusive of 1).
REMISSION END POINTS IN RHEUMATOID ARTHRITIS
remission rates among patients with MTX-refractory active RA who received infliximab in the ATTRACT trial and golimumab in the GO-FORWARD trial were lower than those in infliximab-treated MTX-naive patients in the ASPIRE trial. For all 3 studies, the probability of achieving SDAI remission with active treatment was ,20% for patients with a baseline SDAI score of .30 (further information is available upon request from the corresponding author). When assessed relative to comparator rates within each study, we saw a large difference between treatment groups for lower values of baseline SDAI score (results for the ASPIRE trial are available upon request from the corresponding author). Thus, the results indicated that the baseline SDAI score was a significant covariate in achieving remission among patients receiving active treatment across all 3 trials, including both time points in the ATTRACT and GO-FORWARD trials and week 30 in the ASPIRE trial.
Performance of the DAS28-CRP. DAS28-CRP remission rates were significantly higher in the anti-TNF group than in the comparator group at both time points assessed in each trial (see Supplementary Table  3 , http://onlinelibrary.wiley.com/doi/10.1002/art.39945/ abstract). Across the 3 trials, DAS28-CRP remission rates were 2-3-fold higher than those achieved when using the Boolean, SDAI, and CDAI remission criteria (Table 1) .
Given these dramatically higher rates of remission, sample size calculations would be expected to be affected. As anticipated, based on 100 patients per treatment group, statistical power was higher for DAS28-CRP remission (range 47.6-98.6%, average 81.2%) (see Supplementary Table 4 , http://onlinelibrary.wiley.com/ doi/10.1002/art.39945/abstract) than for each of the other remission end points assessed (i.e., averages of 55.6% for CDAI remission, 59.9% for Boolean remission, and 62.6% for SDAI remission) ( Table 4) . However, there was much lower specificity for true remission. Patients who achieved DAS28-CRP remission had an average of 0.5-1.7 residual swollen joints and as many as 11, while the average for the other remission definitions was 0.2-0.4 residual swollen joints with a maximum of 2 ( Table 2) .
Population effects. Using data from the large ASPIRE trial, in which patients entered with disease duration of up to 5.6 years, we identified additional baseline predictors of SDAI remission. When comparing different patient subgroups for a significantly higher SDAI remission rate when treated with infliximab plus MTX versus MTX alone, we found a CRP level of $1.5 mg/dl, a functional class of III-IV, a Health Assessment Questionnaire disability index (HAQ DI) (18) score of $1.75, an SJC of 15 to ,24, a TJC of ,24, and weight of ,65 kg to be associated with RRs of .2.5 and 95% CIs exclusive of 1 (Table 5) .
DISCUSSION
The advancement of the 2011 ACR/EULAR remission criteria marked a milestone in outcome definitions for RA. For the first time, a data-driven, consensual, and joint definition for the term "remission" was provided. This was more than timely, given that remission constitutes the clear-cut target in many national and international management recommendations for RA. The new criteria served the purpose of homogenizing the view on remission. At the same time, however, several options were offered as potential end points. For the first time, in the present study we directly and comparatively assessed these end points for their stringency, discriminative power, and relevant aspects of their internal/external validity. This is pertinent, as future trials will more likely use remission as a clinically relevant outcome end point, and the question will arise as to which of the recommended scales to employ.
As our major result, remission rates clearly differed among the trials but were very similar when comparing the Boolean definition with the index-based definitions within each trial. One explanation is that the trial populations are very different, with the ASPIRE trial having a population of MTX-naive patients with early RA and the ATTRACT and GO-FORWARD trials having populations of patients with MTX-refractory active RA. Then again, the latter 2 trials differed substantially in their power and sample size requirements. This could be explained by the different time of their conduct (the GO-FORWARD trial was conducted many years after the ATTRACT trial), but more likely by the different inclusion criteria, particularly the lower disease activity requirements, of the ASPIRE trial (see Supplementary Table 1 , http://onlinelibrary.wiley.com/ doi/10.1002/art.39945/abstract). Lower disease activity had been reported as a quite intuitive marker of a patient's ability to reach remission. Further exploration indicated that increased power accompanied lower baseline disease activity levels within all 3 studies (further information is available upon request from the corresponding author). These findings are substantiated by the potential temporal trends indicating that higher remission rates have been achieved in more recently conducted trials, even when using stringent remission criteria, a trend that likely reflects the fact that compared with older studies, more recently conducted clinical trials have patients with shorter disease duration and lower disease activity at baseline (19) .
Studies enrolling patients with high levels of disease activity should therefore consider alternative end points, such as low disease activity, to make recruitment feasible. The higher the achievement rate of the end point, the higher the power of a study, which has been nicely shown in our analysis of hypothetical shifts in remission end points around their established cut points. It should be noted, however, that more stringent remission definitions do not necessitate redefinition of the criteria, but could require alternative targets for specific studies. This is analogous to response criteria (e.g., some studies still use the lenient ACR20 and not the more clinically meaningful ACR50 or ACR70, simply because it would be too difficult to recruit a sufficient number of patients in some RA populations). Alternatively, more contemporary trials (similar to the GO-FORWARD trial), which accept patients with lower levels of disease activity and employ biologic agents with a robust treatment effect, could aim for achievement of remission as defined by ACR/EULAR.
Similarly, and for the sake of interstudy homogeneity, it is better to define a target of low disease activity instead of using remission criteria outside of the ACR/ EULAR recommendations that employ more lenient response definitions. One example is the DAS28, which has been well described to allow for up to 6 swollen joints in remission (20, 21) . As we report here, the ACR/ EULAR definitions allow for a maximum of 1-2 swollen joints in remission. This also corresponds to the maximum number of swollen joints that was determined in a survey during the 2011 ACR/EULAR remission criteria development process and in similar surveys conducted several years earlier (22, 23) . The DAS28 based on the erythrocyte sedimentation rate (DAS28-ESR) was tested during the exercise to derive the ACR/EULAR remission criteria and was found inappropriate due to lacking face validity for "remission" in the 21st century in several studies (24) . Also, testing of nonvalidated DAS28-ESR remission cut points in that exercise indicated that lowering the lenient cut point of 2.6 for remission to 2.4 nullified the predictive validity regarding structural progression. As such, simply modifying cut points to match the proportions of patients with disease in remission according to other indices is not necessarily a useful method for deriving meaningful and valid definitions.
It appears that the slightly stricter definition of remission required by the Boolean criteria narrows the differences between comparator and anti-TNF groups to an extent that power is reduced. Thus, the use of the SDAI and the CDAI could be preferable for better statistical power than the Boolean definition, with nearly the same face validity (i.e., approximately the same mean residual SJC). Since an acute-phase reactant measure, such as the CRP level or the ESR, is likely to be available in a clinical trial, the SDAI may be a good choice to use as the remission end point, as there appears to be little difference in statistical properties compared with the CDAI, and the average statistical power of the SDAI in this analysis was slightly higher than that of the CDAI. However, there is growing use of the CDAI in clinical trials, as it allows better inferences to clinical practice, where it is often the preferred choice.
In summary, trialists essentially have 3 options when deciding on their primary end point: 1) to utilize a true remission definition, which would provide the best possible outcome (7) but requires assessment of ethical and financial acceptability of the much larger sample size requirements; 2) to use alternative targets (low disease activity), which may still answer the important trial questions without making the trial overly large and infeasible; or 3) to use an end point of "pseudo" remission (i.e., the DAS28), which gives the impression of dealing with remission but in fact does not. We clearly speak against this last option, which will ultimately only mislead the readership instead of elucidating the question at stake.
Finally, we also looked for patient subgroups in which remission rates were significantly different between anti-TNF and comparator groups using data from the large ASPIRE trial, which had adequate sample size to allow for multiple subgroup analyses. Significantly higher SDAI remission rates, with RRs of .2.5, were observed in patients receiving infliximab plus MTX compared with patients receiving MTX alone in several patient subgroups (i.e., those with a baseline CRP level of $1.5 mg/dl, a functional class of III-IV, a HAQ DI score of $1.75, an SJC of 15 to ,24, a TJC of ,24, and weight of ,65 kg) ( Table 5 ). It is noteworthy that no significant treatment-by-baseline covariate interactions were observed in this large study. Although, as discussed above, achievement of remission is more difficult in more active disease, the predictors of treatment differences between the 2 active compounds used in the ASPIRE trial were mostly based on markers of active disease. This is intuitive, as the greatest contrasts between 2 active treatments can be observed where the greatest signal of response occurs. Of note, the current analyses were based on comparisons of a TNF inhibitor versus placebo or MTX active comparator in 3 different clinical trial scenarios. As such, findings cannot be extrapolated to trials conducted within markedly different contexts.
Significant advances have been made in the treatment of RA over the past 20 years, and with the hope of developing even more effective therapeutics, achieving a very low level of disease activity like remission is an important outcome to be examined. Our analyses help to inform the use of the more recent ACR/EULAR-endorsed definitions of remission as an end point in RA clinical trials and substantiate remission as an ambitious primary end point for such trials, particularly in situations where large sample sizes are acceptable from an ethical and financial perspective.
